Azitra, Inc. has announced a significant change to its stock structure with a 1-for-10 reverse stock split, effective October 26, 2026. This decision is part of the company's strategy to enhance its stock price and make it more attractive to investors.
The reverse stock split means that every ten shares of Azitra’s common stock will be combined into one share. This move comes after stockholders approved the amendment at the company's annual meeting on June 15, 2026. The board of directors will determine the exact ratio for future splits within a previously approved range.
Azitra, Inc. operates in the pharmaceutical preparations sector, focusing on developing innovative treatments. The company is listed on the NYSE under the ticker symbol AZTR and has been categorized as an emerging growth company.
According to the recent SEC filing (accession number 0001493152-26-048103), the reverse stock split will become effective at 12:01 a.m. Eastern Time on October 26, 2026. The common stock is expected to begin trading on a split-adjusted basis on the same day.
The filing also states that the par value of the common stock will remain unchanged, and no fractional shares will be issued as a result of the reverse stock split. Instead, stockholders who would have received fractional shares will receive cash payments based on the average closing price of the stock over the five trading days preceding the effective date.
This strategic move could have broader implications for the pharmaceutical industry, as companies often consider reverse stock splits to stabilize or increase their stock prices amid challenging market conditions. Azitra's decision may encourage other companies in the sector to evaluate similar strategies.
As Azitra navigates this transition, the company continues to focus on its growth and development in the competitive pharmaceutical landscape. The filing does not specify what actions will follow this announcement, leaving stakeholders awaiting further updates.